Horizon Therapeutics said in December that its thyroid drug Tepezza would likely be in shortage because its contract manufacturer, Catalent, has been directed under the act to process and package COVID-19 vaccines instead of making the drug, according to NPR.
The drugmaker’s CEO, Tim Walbert, said in a Feb. 1 Facebook video: “We’ve heard from many of you. We understand the urgency to resume or start treatment.”
He added that Horizon is working with the FDA to figure out alternative manufacturing methods, NPR reported.
Pfizer also sent a letter to hospitals telling them they may experience short-term supply shortages “due to increased vaccine production,” according to NPR. The shortages may affect cleocin phosphate, an antibiotic; Depo-Medrol, a steroid; and depo-testosterone and testosterone cypionate, used to treat hormonal problems and some breast cancers, NPR reported.
Read the full article here.
More articles on pharmacy:
Sanofi launches trial for 2nd COVID-19 vaccine candidate
Emergency departments struggling to help patients with addiction during pandemic
How free COVID-19 vaccines could be affecting pharmacies’ finances
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
